Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00198068 · ClinicalTrials.gov registry record
Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)
A clinical trial of Systemic Lupus Erythematosus and Antiphospholipid Syndrome, sponsored by Hospital for Special Surgery, New York.
- Recruiting
- Registry status
- 700
- Enrollment target
- 10
- Study locations
NCT00198068: Recruiting study of Systemic Lupus Erythematosus and Antiphospholipid Syndrome, sponsored by Hospital for Special Surgery, New York.
NCT00198068 is a study of Systemic Lupus Erythematosus and Antiphospholipid Syndrome that is actively recruiting participants, run by Hospital for Special Surgery, New York. The registered enrollment target is 700 participants, above the 373-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (88% higher). The trial reports 10 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00198068, a study of Systemic Lupus Erythematosus and Antiphospholipid Syndrome, is actively recruiting participants, sponsored by Hospital for Special Surgery, New York.
- RECRUITING
- Registry status
- 700 participants
- Enrollment target
- 10
- Study locations
Study Summary
The PROMISSE Study is an observational study of 700 pregnant patients, enrolled at nine major clinical centers. The purpose of the study is 1) to determine whether certain proteins (called complement split products) that can injure healthy organs can be used to predict poor pregnancy outcome in patients with systemic lupus erythematosus (SLE) and anti-phospholipid syndrome (APS), and/or 2) to determine whether elevated levels of circulating antiangiogenic factors predict pregnancy complications in patients with aPL antibodies and/or SLE.
Primary Outcome
Fetal death occurring after 12 weeks' gestation and not explained by chromosomal abnormalities, anatomic malformations, or congenital infections.
Conditions Studied
Study Locations (10)
New York
- NYU Langone Medical Center/Hospital for Joint Diseases - New York
- Hospital for Special Surgery - New York
- Columbia University Medical Center - New York
Illinois
- Northwestern University - Chicago
- University of Chicago - Chicago
Maryland
- Johns Hopkins Hospital - Baltimore
Oklahoma
- Oklahoma Medical Research Foundation - Oklahoma City
Utah
- University of Utah Salt Lake City - Salt Lake City
Ontario
- Mt. Sinai Hospital - Toronto
Other
- Guy's & St Thomas' NHS Foundation Trust - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2003-09 |
| Est. Completion | 2026-03 |
What NCT00198068 shows while recruiting
NCT00198068 is an observational study that tracks outcomes without assigning an intervention. The registered 700 participants enrollment target is mid-sized for trials with a published cap, above the 373-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (88% higher).
The record links to 2 conditions, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 0 interventions.
NCT00198068 lists 10 locations in 7 states (New York, Illinois, Maryland).
Frequently Asked Questions
What is clinical trial NCT00198068 about?
NCT00198068 is a clinical study titled "Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)". The PROMISSE Study is an observational study of 700 pregnant patients, enrolled at nine major clinical centers. The purpose of the study is 1) to determine whether certain proteins (called complement split products) that can injure healthy organs can be used to predict poor pregnancy outcome in pati...
What is the current status of trial NCT00198068?
This trial is currently recruiting. The enrollment target is 700 participants. The study started on 2003-09. Estimated completion is 2026-03.
What conditions does trial NCT00198068 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus, Antiphospholipid Syndrome.
Who is sponsoring clinical trial NCT00198068?
This trial is sponsored by Hospital for Special Surgery, New York, which has 194 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00198068 being conducted?
This trial has 10 study locations across Illinois, Maryland, New York, Oklahoma, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00198068's enrollment target sits among peer trials
700 12th of 99 higher than 88 of 99 other Systemic Lupus Erythematosus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Systemic Lupus Erythematosus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
RECRUITING · Phase 3
-
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)
RECRUITING · Phase 1
-
A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus
RECRUITING · Phase 1
-
Creating Health Course Study for People With Rheumatological Conditions
RECRUITING · NA
-
Electroencephalogram Recording in Patients With Systemic Lupus Erythematosus
RECRUITING
-
Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900419 · 700 participants
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
- NCT01804686 · 700 participants · Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
- NCT02107989 · 700 participants
Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database
- NCT02129543 · 700 participants
Immune Reconstitution in Stem Cell Transplant Recipients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia